Selenium Sulfide side effects: what 936 FDA adverse event reports show

Selenium Sulfide · 16 reaction terms · 253 drug–reaction co-reports · data 2026-09-14

Drug class

Not stated in label

Who reports

936 reports · 39% serious · 23 with death outcome · 46% female

openFDA FAERS counts, all years, deduplication not applied

Used for

A liquid antiseborrheic, antifungal preparation for the treatment of seborrheic dermatitis of the scalp, dandruff and tinea versicolor. Urea hydrates and is useful for conditions such as dry scalp.

FDA label, Indications and Usage

What it is

DESCRIPTION: A liquid antiseborrheic, antifungal preparation for topical application.

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 12 strongest signals

Reporting / coding artifact 6No label text to screen 6

What the badges mean

Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
No label text to screen No validated FDA label was retrievable for this product, so the screen could not run. Disproportionality only.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 4 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Hair colour changes	55	98.4 76.1–127.2ROR 104.5 · χ² 5,185 / p <1e-300	94.8 EB05 75.6 · IC025 +5.3 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=3 · 94% consumer	no trial data cached
Product odour abnormal	30	64.9 45.6–92.4ROR 67.0 · χ² 1,820 / p <1e-300	62.3 EB05 45.7 · IC025 +4.4 3/3 methods agree	Reporting / coding artifact	90% consumer	no trial data cached
Hair texture abnormal	31	51.6 36.5–73.0ROR 53.3 · χ² 1,485 / p <1e-300	50.0 EB05 36.9 · IC025 +4.2 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=1 · 94% consumer	no trial data cached
Drug effect less than expected	11	17.5 9.7–31.5ROR 17.7 · χ² 155 / p 7e-36	16.3 EB05 8.7 · IC025 +2.3 3/3 methods agree	Reporting / coding artifact	–	no trial data cached
Economic problem	8	11.6 5.8–23.2ROR 11.7 · χ² 67 / p 1e-16	9.0 EB05 4.2 · IC025 +1.6 3/3 methods agree	Reporting / coding artifact	serious PRR 18.8	no trial data cached
Application site pain	7	7.1 3.4–14.9ROR 7.2 · χ² 31 / p 1e-8	5.2 EB05 2.7 · IC025 +1.0 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=1	no trial data cached
Skin irritation	14	6.8 4.1–11.5ROR 6.9 · χ² 64 / p 6e-16	5.7 EB05 3.6 · IC025 +1.6 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=2	no trial data cached
No adverse event	51	6.4 4.9–8.4ROR 6.8 · χ² 231 / p 2e-52	6.1 EB05 4.8 · IC025 +2.1 3/3 methods agree	Reporting / coding artifact	94% consumer	no trial data cached
Product administered at inappropriate site	5	6.2 2.6–14.8ROR 6.2 · χ² 17 / p 2e-5	4.2 EB05 2.0 · IC025 +0.5	Reporting / coding artifact	–	no trial data cached
Drug effective for unapproved indication	7	5.4 2.6–11.2ROR 5.4 · χ² 21 / p 3e-6	4.1 EB05 2.2 · IC025 +0.8 3/3 methods agree	No label text to screen label has no adverse-reaction text	–	no trial data cached
Expired product administered	7	4.7 2.3–9.9ROR 4.8 · χ² 17 / p 2e-5	3.7 EB05 2.0 · IC025 +0.6	Reporting / coding artifact	serious n=1	no trial data cached
Skin burning sensation	12	3.8 2.2–6.6ROR 3.8 · χ² 22 / p 1e-6	3.4 EB05 2.1 · IC025 +0.8 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 7.2	no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Hair colour changes	55	98.4 76.1–127.2ROR 104.5 · χ² 5,185 / p <1e-300	94.8 EB05 75.6 · IC025 +5.3 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=3 · 94% consumer	no trial data cached
No adverse event	51	6.4 4.9–8.4ROR 6.8 · χ² 231 / p 2e-52	6.1 EB05 4.8 · IC025 +2.1 3/3 methods agree	Reporting / coding artifact	94% consumer	no trial data cached
Hair texture abnormal	31	51.6 36.5–73.0ROR 53.3 · χ² 1,485 / p <1e-300	50.0 EB05 36.9 · IC025 +4.2 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=1 · 94% consumer	no trial data cached
Product odour abnormal	30	64.9 45.6–92.4ROR 67.0 · χ² 1,820 / p <1e-300	62.3 EB05 45.7 · IC025 +4.4 3/3 methods agree	Reporting / coding artifact	90% consumer	no trial data cached
Skin irritation	14	6.8 4.1–11.5ROR 6.9 · χ² 64 / p 6e-16	5.7 EB05 3.6 · IC025 +1.6 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=2	no trial data cached
Skin burning sensation	12	3.8 2.2–6.6ROR 3.8 · χ² 22 / p 1e-6	3.4 EB05 2.1 · IC025 +0.8 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 7.2	no trial data cached
Drug effect less than expected	11	17.5 9.7–31.5ROR 17.7 · χ² 155 / p 7e-36	16.3 EB05 8.7 · IC025 +2.3 3/3 methods agree	Reporting / coding artifact	–	no trial data cached
Economic problem	8	11.6 5.8–23.2ROR 11.7 · χ² 67 / p 1e-16	9.0 EB05 4.2 · IC025 +1.6 3/3 methods agree	Reporting / coding artifact	serious PRR 18.8	no trial data cached
Expired product administered	7	4.7 2.3–9.9ROR 4.8 · χ² 17 / p 2e-5	3.7 EB05 2.0 · IC025 +0.6	Reporting / coding artifact	serious n=1	no trial data cached
Drug effective for unapproved indication	7	5.4 2.6–11.2ROR 5.4 · χ² 21 / p 3e-6	4.1 EB05 2.2 · IC025 +0.8 3/3 methods agree	No label text to screen label has no adverse-reaction text	–	no trial data cached
Application site pain	7	7.1 3.4–14.9ROR 7.2 · χ² 31 / p 1e-8	5.2 EB05 2.7 · IC025 +1.0 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious n=1	no trial data cached
Product administered at inappropriate site	5	6.2 2.6–14.8ROR 6.2 · χ² 17 / p 2e-5	4.2 EB05 2.0 · IC025 +0.5	Reporting / coding artifact	–	no trial data cached
Application site erythema	4	3.4 1.3–9.1ROR 3.4 · χ² 5 / p 0.016	2.7 EB05 1.2 · IC025 -0.3 PRR-only: not supported by EBGM or IC	No label text to screen label has no adverse-reaction text	–	no trial data cached
Coronary artery occlusion	4	6.5 2.4–17.3ROR 6.5 · χ² 14 / p 1e-4	4.1 EB05 1.8 · IC025 +0.2	No label text to screen label has no adverse-reaction text	serious PRR 9.6	no trial data cached
Application site irritation	4	7.2 2.7–19.2ROR 7.2 · χ² 16 / p 4e-5	4.4 EB05 1.9 · IC025 +0.3	No label text to screen label has no adverse-reaction text	–	no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Selenium Sulfide?

In FDA FAERS, the most frequently co-reported reaction terms for Selenium Sulfide are hair colour changes, hair texture abnormal, skin irritation, skin burning sensation, drug effective for unapproved indication, application site pain. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Selenium Sulfide have an FDA boxed warning?

No. The FDA label retrieved for Selenium Sulfide has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Selenium Sulfide causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID a72001ce-42a2-4708-e053-2995a90a7593, effective 20251106; matched on openfda.generic_name.exact:"SELENIUM SULFIDE" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG")
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 16 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.